Obesity and Type 2 Diabetes

Being overweight can put you at risk for other weight-related health conditions.  Consider joining a clinical research study.

Researchers are enrolling adult volunteers in a clinical research study evaluating the safety and effectiveness of an investigational medication for the treatment of individuals with type 2 diabetes who are obese or overweight and are at increased cardiovascular risk.

No health Insurance required.

For more information, or to see if you qualify to participate in this study, call Metabolic Research Institute Inc. (561) 802-3060, ext. 8036 or visit: www.metabolic-institute.com/DM2andObesity/

Hypertension and CKD

Researchers are evaluating the safety and efficacy of an investigational drug for people with high blood pressure and chronic kidney disease.

No health Insurance is required.

Eczema Clinical Study

Looking for relief from itchy or sensitive skin? Consider joining a clinical research study.

No health Insurance required.

For more information call Metabolic Research Institute Inc. (561) 802-3060, ext. 8036 or visit:  https://www.metabolic-institute.com/eczema-study/

Type 2 Diabetes Using Trulicity® (dulaglutide)

Do You have Type 2 Diabetes?

Are you using Trulicity® (dulaglutide) to control your blood sugar levels?

lndividuals who are diagnosed with Type 2 Diabetes and are using Trulicity® (dulaglutide) to control their blood sugar levels may qualify for a local clinical trial.

This study will investigate the safety and effectiveness of switching from weekly Trulicity® (dulaglutide) in adult volunteers diagnosed with Type 2 Diabetes.

For more information, call Metabolic Research Institute Inc. (561) 802-3060, ext. 8036 or visit: https://www.metabolic-institute.com/dm2-study/

Obesity and Cardiovascular Disease Study

Once Weekly Injection for Type 2 Diabetes

For adults with Type 2 Diabetes this clinical study may be of interest to you.

We are looking for adults 18 years of age or older who are diagnosed with Type 2 Diabetes.  The clinical study will evaluate the effectiveness of a once-weekly investigational combination product, IcoSema, in participants with type 2 diabetes inadequately controlled with daily basal insulin.

For more information, or to see if you qualify to participate in this study, call Metabolic Research Institute Inc. (561) 802-3060, ext. 8036 or visit: https://www.metabolic-institute.com/weekly-injection/